• Latest
  • Sectors
    • Pharma
    • Biotech
    • MedTech
    • Regulation & Industry
  • In-House
  • Careers
  • Events
    • Events
    • Events News
    • Events Videos
    • Webinars
  • Insights
    • Whitepapers
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Copyright compliance in the life sciences industry
race-uphill-sand-dune
31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

In-house counsel
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
4 November 2026   AI agents are no longer just helping patent lawyers with their workload. Some are now doing the work themselves. In-house counsel from Insitro, Illumina, 10x Genomics and Invenra discuss how much can be handed over and whether humans could be replaced.
Careers
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
4 November 2026   Joining in Wisconsin, the senior counsel brings “sophisticated” trademark experience and leadership, and counts biotechnology among her sectors.
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026   With budgets under pressure, counsel from Pfizer, ALX Oncology and BioMarin share how they are reassessing portfolios, trimming costs and prioritising key markets at LSPN Fall.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos
Westlaw publisher scores landmark AI copyright win in US appeals court
Beyond the primary patent: How pharma can build competitive barriers
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
The UPC plugs another gap in its procedural rulebook
Brown Rudnick lands largest lateral IP team hire in firm history
Pharmascience v Janssen: Canada court updates methods of medical treatment protection

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin